Efficacy and Tolerability of Weekly Docetaxel, Cisplatin, and 5-Fluorouracil for Locally Advanced or Metastatic Gastric Cancer Patients with ECOG Performance Scores of 1 and 2

  • Turkeli, Mehmet (Department of Medical Oncology, Faculty of Medicine, Ataturk University Erzurum) ;
  • Aldemir, Mehmet Naci (Department of Medical Oncology, Faculty of Medicine, Ataturk University Erzurum) ;
  • Cayir, Kerim (Department of Medical Oncology, Faculty of Medicine, Ataturk University Erzurum) ;
  • Simsek, Melih (Department of Medical Oncology, Faculty of Medicine, Ataturk University Erzurum) ;
  • Bilici, Mehmet (Department of Medical Oncology, Faculty of Medicine, Ataturk University Erzurum) ;
  • Tekin, Salim Basol (Department of Medical Oncology, Faculty of Medicine, Ataturk University Erzurum) ;
  • Yildirim, Nilgun (Department of Medical Oncology, Faculty of Medicine, Ataturk University Erzurum) ;
  • Bilen, Nurhan (Department of Internal Medicine, Faculty of Medicine, Ataturk University Erzurum) ;
  • Makas, Ibrahim (Department of Internal Medicine, Faculty of Medicine, Ataturk University Erzurum)
  • Published : 2015.03.04


Background: Docetaxel, cisplatin, 5-fluorouracil (DCF) given every three weeks is an effective, but palliative regimen and significantly toxic especially in patients who have a low performance score. Here, we aimed to evaluate the efficacy and tolerability of a weekly formulation of DCF in locally advanced and metastatic gastric cancer patients. Materials and Methods: 64 gastric cancer patients (13 locally advanced and 51 metastatic) whose ECOG (Eastern Cooperative Oncology Group) performance status (PS) was 1-2 and who were treated with at least two cycles of weekly DCF protocol as first-line treatment were included retrospectively. The weekly DCF protocol included $25mg/m^2$ docetaxel, $25mg/m^2$ cisplatin, and 24 hours infusion of $750mg/m^2$ 5-fluorouracil, repeated every week. Disease and patient characteristics, prognostic factors, treatment response, grade 3-4 toxicity related to treatment, progression free survival (PFS) and overall survival (OS) were evaluated. Results: Of the patients, 41 were male and 23 were female; the median age was 63 (29-82) years. Forty-one patients were ECOG-1 and 23 were ECOG-2. Of the total, 81.2% received at least three cycles of chemotherapy. Partial response was observed in 28.1% and stabilization in 29.7%. Overall, the disease was controlled in 57.8% whereas progression was noted in 42.2%. The median time to progression was 4 months (95%CI, 2.8-5.2 months) and median overall survival was 12 months (95%CI, 9.2-14.8 months). The evaluation of patients for grade 3-4 toxicity revealed that 10.9% had anemia, 7.8% had thrombocytopenia and 10.9% had neutropenia. Non-hematologic toxicity included renal toxicity (7.8%) and thrombosis (1.6%). Conclusions: In patients with locally advanced or metastatic gastric cancer who were not candidates for DCF administered every-3-weeks, a weekly formulation of DCF demonstrated modest activity with minimal hematologic toxicity, suggesting that weekly DCF is a reasonable treatment option for such patients.


  1. Alici S, Buyukberber S, Alkis N, et al (2013). Low-dose docetaxel/cisplatin - leucovorin and 46 hour infusional fluorouracil in metastatic gastric carcinoma. Anatolian Society of Medical Oncology. Asian Pac J Cancer Prev, 14, 423-7.
  2. Eisenhauera EA, Therasseb P, Bogaertsc J, et al (2009). New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) Eur J Cancer, 45, 228-47
  3. Camps C, Massuti B, Jimenez A, et al (2006). Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. Ann Oncol, 17, 467-72.
  4. Chen XL1, Chen XZ, Yang C, et al (2013). Docetaxel, cisplatin and fluorouracil (DCF) regimen compared with non-taxanecontaining palliative chemotherapy for gastric carcinoma: a systematic review and meta-analysis. PLoS One. 8, 60320
  5. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
  6. Hainsworth JD, Howard AB III, Erland JB et al (1998). Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol, 16, 2164-8.
  7. Inal A, Kaplan MA, Kucukoner M, et al (2012). Prognostic factors in first-line chemotherapy treated metastatic gastric cancer patients: a retrospective study. Asian Pac J Cancer Prev, 13, 3869-72.
  8. Kamangar F, Dores GM, Anderson WF (2006). Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol, 24, 2137-50.
  9. Kim JG, Ryoo BY, Park YH, et al (2008). Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy. Cancer Chemother Pharmacol, 61, 301-7
  10. Ozdemir NY, Abali H, Oksüzoğlu B, et al (2010). The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma. Med Oncol, 27, 680-4.
  11. Schuette W, Nagel S, Blankenburg T, et al (2005). Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol, 23, 8389-95
  12. Tabernero J, Climent MA, Lluch A et al (2004). A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol, 15, 1358-65.
  13. Van Cutsem E, Moiseyenko VM, Tjulandin SA, Majlis A, Constenla M et al (2006). V325 Study Group Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol, 24, 4991-7.
  14. Wang B, Zhang W, Hong X, Guo Y, Li J (2009). Phase I doseescalating study of 24h continuous infusion of 5-fluorouracil in combination with weekly docetaxel and cisplatin in patients with advanced gastric cancer. Cancer Chemother Pharmacol. 63, 213-8.
  15. Wagner AD, Grothe W, Haerting J, et al (2006). Chemotherapy in advanced gastric cancer: a systematic review and metaanalysis based on aggregate data. JCO, 24, 2903-9

Cited by

  1. Modified schedules of DCF chemotherapy for advanced gastric cancer vol.28, pp.2, 2017,